Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1Phase 2/3 1

Status

Completed 5Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 28INDUSTRY 7FED 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 2Thoracic 1Other 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 3Breast Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Stomatitis 1Rectal Neoplasms 1Pain, Postoperative 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Mucositis 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Water × Clear all
NCT07321847 2026-01-07

INJECTABL-3

Immunophotonics, Inc.

Phase 2/3 Not yet recruiting
717 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

G1 Therapeutics, Inc.

Phase 3 Completed
194 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04863248 2023-04-14

PRESERVE 4

G1 Therapeutics, Inc.

Phase 2 Terminated
10 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02324335 2019-01-16

Brilacidin

Innovation Pharmaceuticals, Inc.

Phase 2 Completed
61 enrolled 12 charts
Head & NeckOther

Head and Neck Neoplasms, Stomatitis, Mucositis

NCT01803295 2017-06-16

OPTIMA

UroGen Pharma Ltd.

Phase NA Completed
80 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01479244 2017-02-27

PRESENT

Galena Biopharma, Inc.

Phase 3 Completed
758 enrolled
Breast

Breast Neoplasms

NCT02522598 2016-09-29

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy

Vivozon, Inc.

Phase 2 Completed
38 enrolled

Pain, Postoperative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡